Clinical trial
Trial of Pemetrexed for Patients With Pancreatic Cancer Which Cannot be Treated…
NCT00490373 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00490373 |
|---|---|
| Title | Trial of Pemetrexed for Patients With Pancreatic Cancer Which Cannot be Treated With Surgery or is Metastatic |
| Official title | A Phase 2 Trial of ALIMTA in Pretreated Patients With Unresectable or Metastatic Cancer of the Pancreas |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | pemetrexed |
| Enrollment | 52 |
| Start date | Oct 1, 2003 |
| Completion | Apr 1, 2005 |
| First posted | Jun 22, 2007 |
| Last update posted | Jun 22, 2007 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: